Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-5 (cancelled)

Claim 6. (currently amended) The method of claim $[\underline{19}]$ $\underline{23}$, wherein the composition is administered in a form of a cream, a gel, a gelatin capsule or a patch.

Claim 7. (currently amended) The method of claim [19] $\underline{23}$, wherein the at least one 12-HETE further comprises 12(R)-HETE.

Claim 8. (currently amended) The method of claim [19] $\underline{23}$, wherein the at least one 12-HETE further comprises 12(S)-HETE.

Claims 9-10 (cancelled)

Claim 11. (currently amended) The method of claim [20] $\underline{24}$, wherein the composition is administered in a form of a cream, a gel, a gelatin capsule or a patch.

Claims 12-13 (cancelled)

Claim 14. (withdrawn) A method of treating obesity in an animal or a human comprising administering the human or the animal an effective amount of a composition comprising an arachidonic acid oxidation cascade metabolite, wherein the metabolite is 12-(S)HETE, 12-(R)HETE, 11, 12-EET, or a mixture thereof.

Claim 15. (withdrawn) The method of claim 14, wherein the composition is administered in a form of a cream, a gel, a gelatin capsule or a patch.

Claim 16. (withdrawn) The method of claim 14, wherein the at least one 12-HETE further comprises 12(R)-HETE.

Claim 17. (withdrawn) The method of claim 14, wherein the at least one 12-HETE further comprises 12(S)-HETE.

Claim 18. (withdrawn) A method of inhibiting an everage amount of triacylglycerides per fibroblast or pre-adipocyte cell in an animal or a human comprising administering to the animal or the human an effective amount of a composition comprising 12-HETE, 11,12-EET, or a mixture thereof.

Claims 19-20. (cancelled)

Claim 21. (currently amended) The method of claim $\frac{20}{24}$, wherein the metabolite comprises 12(R)-HETE.

Claim 22. (currently amended) The method of claim $\frac{20}{24}$, wherein the metabolite comprises 12(S)-HETE.

Claim 23. (New) A method of inhibiting differentiation of a fibroblast to an adipocyte comprising administering to a human or an animal either as a nutriceutical formulation or topically on the areas concerned by localized excess subcutaneous fat deposits an effective amount of a composition comprising at least one of 12-hydroxyeicosatetraenoic acid or 12-HETE and 11,12-epoxyeicosatetraenoic acid or 11,12-EET.

Claim 24. (New) A method of inhibiting differentiation of a fibroblast to an adipocyte comprising administering to a human or an animal either as a nutriceutical formulation or topically on the areas concerned by localized excess subcutaneous fat deposits an effective amount of a composition comprising an arachidonic oxidation cascade metabolite, wherein the metabolite is the stereoisomer S of 12-hydroxyeicosatetraenoic acid or 12(S)-HETE, the stereoisomer R of 12-hydroxyeicosatetraenoic acid or 12(R)-HETE, the 11,12-hydroxyeicosatriaenoic acid or the 11,12-EET.